Literature DB >> 31600832

Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy.

Lauren Bowen Reoma1, Christopher Julius Trindade2, Maria Chiara Monaco3, Jamie Solis1, Marta Garcia Montojo1, Phuong Vu4, Kory Johnson5, Erin Beck6, Govind Nair6, Omar I Khan7, Marta Quezado8, Stephen M Hewitt2, Daniel S Reich6, Richard Childs4, Avindra Nath1.   

Abstract

OBJECTIVE: JC virus (JCV) infection is a lytic infection of oligodendrocytes in progressive multifocal leukoencephalopathy; less common forms of central nervous system manifestations associated with JCV infection include granule cell neuronopathy, encephalopathy, and meningitis. Presented is the first case of fatal JCV encephalopathy after immunosuppressive therapy that included ruxolitinib.
METHODS: Postmortem analysis included next generation sequencing, Sanger sequencing, tissue immunohistochemistry, and formalin-fixed hemisphere 7T magnetic resonance imaging.
RESULTS: JCV DNA isolated from postmortem tissue samples identified a novel 12bp insertion that altered the transcription site binding pattern in an otherwise "wild-type virus," which has long been thought to be the nonpathogenic form of JCV. Anti-VP1 staining demonstrated infection in cortical neurons, hippocampal neurons, and glial and endothelial cells.
INTERPRETATION: This expands the spectrum of identified JCV diseases associated with broad-spectrum immunosuppression, including JAK-STAT inhibitors, and sheds light on an additional neurotropic virus strain of the archetype variety. ANN NEUROL 2019;86:878-884.
© 2019 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31600832      PMCID: PMC8189164          DOI: 10.1002/ana.25608

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   11.274


  6 in total

1.  Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Authors:  Rowan Wathes; Simon Moule; Dragana Milojkovic
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

2.  JC virus granule cell neuronopathy is associated with VP1 C terminus mutants.

Authors:  Xin Dang; Jose E Vidal; Augusto C Penalva de Oliveira; David M Simpson; Susan Morgello; Jonathan H Hecht; Long H Ngo; Igor J Koralnik
Journal:  J Gen Virol       Date:  2011-09-21       Impact factor: 3.891

3.  Fatal ruxolitinib-related JC virus meningitis.

Authors:  Begoña Ballesta; Héctor González; Vicente Martín; Juan J Ballesta
Journal:  J Neurovirol       Date:  2017-08-08       Impact factor: 2.643

4.  Conditionally immortalized human podocyte cell lines established from urine.

Authors:  Toru Sakairi; Yoshifusa Abe; Hiroshi Kajiyama; Linda D Bartlett; Lilian V Howard; Parmijit S Jat; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-02

Review 5.  Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.

Authors:  Christa S Zerbe; Beatriz E Marciano; Rohit K Katial; Carah B Santos; Nick Adamo; Amy P Hsu; Mary E Hanks; Dirk N Darnell; Martha M Quezado; Cathleen Frein; Lisa A Barnhart; Victoria L Anderson; Gulbu Uzel; Alexandra F Freeman; Andrea Lisco; Avindra Nath; Eugene O Major; Elizabeth P Sampaio; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-01-06       Impact factor: 9.079

6.  JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant.

Authors:  Xin Dang; Christian Wüthrich; Jennifer Gordon; Hirofumi Sawa; Igor J Koralnik
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

  6 in total
  7 in total

Review 1.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

2.  Database and Statistical Analyses of Transcription Factor Binding Sites in the Non-Coding Control Region of JC Virus.

Authors:  Kazuo Nakamichi; Toshio Shimokawa
Journal:  Viruses       Date:  2021-11-19       Impact factor: 5.048

Review 3.  Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.

Authors:  Olaf Neth; Peter Olbrich; Angela Deyà-Martínez; Jaques G Rivière; Pérsio Roxo-Junior; Jan Ramakers; Markéta Bloomfield; Paloma Guisado Hernandez; Pilar Blanco Lobo; Soraya Regina Abu Jamra; Ana Esteve-Sole; Veronika Kanderova; Ana García-García; Mireia Lopez-Corbeto; Natalia Martinez Pomar; Andrea Martín-Nalda; Laia Alsina
Journal:  J Clin Immunol       Date:  2022-04-29       Impact factor: 8.542

Review 4.  Understanding polyomavirus CNS disease - a perspective from mouse models.

Authors:  Katelyn N Ayers; Sarah N Carey; Aron E Lukacher
Journal:  FEBS J       Date:  2021-07-02       Impact factor: 5.622

5.  Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic.

Authors:  Fabio Pires de Souza Santos; Renato Sampaio Tavares; Katia Borgia Barbosa Pagnano
Journal:  Hematol Transfus Cell Ther       Date:  2020-06-19

Review 6.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937

7.  JC virus granule cell neuronopathy associated with Ruxolitinib: A case report and review of the literature.

Authors:  Kentaro Nakayama; Masataka Nakamura; Akiko Konishi; Satoshi Kaneko; Kazuo Nakamichi; Masayuki Saijo; Yusuke Yakushiji; Hirofumi Kusaka
Journal:  eNeurologicalSci       Date:  2020-09-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.